9 results on '"Corsico, Angelo"'
Search Results
2. Clinical and functional characteristics of individuals with alpha-1 antitrypsin deficiency: EARCO international registry.
- Author
-
Miravitlles M, Turner AM, Torres-Duran M, Tanash H, Rodríguez-García C, López-Campos JL, Chlumsky J, Guimaraes C, Rodríguez-Hermosa JL, Corsico A, Martinez-González C, Hernández-Pérez JM, Bustamante A, Parr DG, Casas-Maldonado F, Hecimovic A, Janssens W, Lara B, Barrecheguren M, González C, Stolk J, Esquinas C, and Clarenbach CF
- Subjects
- Humans, Male, alpha 1-Antitrypsin genetics, Cross-Sectional Studies, Genotype, Prospective Studies, Registries, alpha 1-Antitrypsin Deficiency diagnosis, alpha 1-Antitrypsin Deficiency epidemiology, alpha 1-Antitrypsin Deficiency genetics, Bronchiectasis diagnosis, Bronchiectasis epidemiology, Pulmonary Disease, Chronic Obstructive genetics, Pulmonary Emphysema diagnosis, Pulmonary Emphysema epidemiology, Pulmonary Emphysema complications
- Abstract
Background: Alpha-1 antitrypsin deficiency (AATD) is a rare disease that is associated with an increased risk of pulmonary emphysema. The European AATD Research Collaboration (EARCO) international registry was founded with the objective of characterising the individuals with AATD and investigating their natural history., Methods: The EARCO registry is an international, observational and prospective study of individuals with AATD, defined as AAT serum levels < 11 μM and/or proteinase inhibitor genotypes PI*ZZ, PI*SZ and compound heterozygotes or homozygotes of other rare deficient variants. We describe the characteristics of the individuals included from February 2020 to May 2022., Results: A total of 1044 individuals from 15 countries were analysed. The most frequent genotype was PI*ZZ (60.2%), followed by PI*SZ (29.2%). Among PI*ZZ patients, emphysema was the most frequent lung disease (57.2%) followed by COPD (57.2%) and bronchiectasis (22%). Up to 76.4% had concordant values of FEV1(%) and KCO(%). Those with impairment in FEV1(%) alone had more frequently bronchiectasis and asthma and those with impairment in KCO(%) alone had more frequent emphysema and liver disease. Multivariate analysis showed that advanced age, male sex, exacerbations, increased blood platelets and neutrophils, augmentation and lower AAT serum levels were associated with worse FEV1(%)., Conclusions: EARCO has recruited > 1000 individuals with AATD from 15 countries in its first 2 years. Baseline cross sectional data provide relevant information about the clinical phenotypes of the disease, the patterns of functional impairment and factors associated with poor lung function. Trial registration www., Clinicaltrials: gov (ID: NCT04180319)., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
3. Respiratory viruses in stable bronchiectasis: A multicenter evaluation in Northern Italy.
- Author
-
Aliberti S, Gramegna A, Zucchetti S, Simonetta E, Amati F, Castelli D, Cavallero A, Franceschi E, Conio V, Grosso A, Faverio P, Radovanovic D, Terraneo S, Di Marco F, Pesci A, Airoldi C, Valenti V, Corsico A, Santus P, Centanni S, Sotgiu G, and Blasi F
- Subjects
- Humans, Italy epidemiology, Bronchiectasis epidemiology, Viruses
- Published
- 2022
- Full Text
- View/download PDF
4. Thrombocytosis during Stable State Predicts Mortality in Bronchiectasis.
- Author
-
Aliberti S, Sotgiu G, Gramegna A, McDonnell MJ, Polverino E, Torres A, Goeminne PC, Dimakou K, Shteinberg M, Sibila O, Conio V, Fardon TC, Rutherford R, Dore S, Saderi L, Faverio P, Amati F, Corsico AG, Blasi F, and Chalmers JD
- Subjects
- Adult, Aged, Female, Hospitalization, Humans, Male, Quality of Life, Severity of Illness Index, Bronchiectasis complications, Thrombocytosis epidemiology
- Abstract
Rationale: Although platelets are considered key inflammatory mediators in respiratory diseases, their role in bronchiectasis has not been fully explored. Objectives: We hypothesized that thrombocytosis in stable state may be associated with bronchiectasis severity and worse clinical outcomes. Methods: Patients with bronchiectasis have been enrolled from 10 centers in Europe and Israel, with platelet count recorded during stable state. The primary outcome was 5-year all-cause mortality. Secondary outcomes included exacerbations, hospitalizations, and mortality at 1, 2, and 3-year follow-up. Analyses were conducted using logistic regression after adjustment for confounding variables. Results: Among the 1,771 patients (median age, 67 yr; 63.4% female) included, 136 (7.7%) had thrombocytosis. Patients with thrombocytosis had a significantly higher disease severity, worse quality of life, higher number of exacerbations and hospitalizations, and higher mortality rate at both 3-year (23 [22.8%] vs. 83 [8.5%], respectively; P < 0.01) and 5-year (26 [35.1%] vs. 116 [15.9%], respectively; P < 0.01) in comparison with those with normal platelet count. Thrombocytosis was significantly associated with hospitalizations because of severe exacerbations (odds ratio [OR], 1.83; 95% confidence interval [CI], 1.20-2.79; P = 0.01) after 1-year follow-up, as well as increased 3-year (OR, 3.06; 95% CI, 1.74-5.39; P < 0.01) and 5-year (OR, 2.46; 95% CI, 1.39-4.37; P < 0.01) mortality. Conclusions: Platelets represent a cheap and easy-to-evaluate biomarker, and the presence of thrombocytosis during stable state is associated with disease severity, hospitalizations because of exacerbations, poor quality of life, and mortality in adults with bronchiectasis.
- Published
- 2021
- Full Text
- View/download PDF
5. The prevalence of bronchiectasis in patients with alpha-1 antitrypsin deficiency: initial report of EARCO.
- Author
-
Stockley, Robert A., Pye, Anita, De Soyza, Joshua, Turner, Alice M., Miravitlles, Marc, the EARCO study investigators, Torres-Duran, María, Tanash, Hanan, Rodríguez-García, Carlota, López-Campos, José Luis, Chlumsky, Jan, Guimaraes, Catarina, Rodríguez-Hermosa, Juan Luis, Corsico, Angelo, Martinez-González, Cristina, Hernández-Pérez, José María, Bustamante, Ana, Parr, David G., Casas-Maldonado, Francisco, and Hecimovic, Ana
- Subjects
ALPHA 1-antitrypsin ,BRONCHIECTASIS ,TRYPSIN inhibitors ,COMPUTED tomography - Abstract
Background: Although bronchiectasis has been recognised as a feature of some patients with Alpha1-Antitrypsin deficiency the prevalence and characteristics are not widely known. We wished to determine the prevalence of bronchiectasis and patient characteristics. The first cohort of patients recruited to the EARCO (European Alpha1 Research Collaboration) International Registry data base by the end of 2021 was analysed for radiological evidence of both emphysema and bronchiectasis as well as baseline demographic features. Results: Of the first 505 patients with the PiZZ genotype entered into the data base 418 (82.8%) had a reported CT scan. There were 77 (18.4%) with a normal scan and 38 (9.1%) with bronchiectasis alone. These 2 groups were predominantly female never smokers and had lung function in the normal range. The remaining 303 (72.5%) ZZ patients all had emphysema on the scan and 113 (27%) had additional evidence of bronchiectasis. Conclusions: The data indicates the bronchiectasis alone is a feature of 9.1% of patients with the PiZZ genotype of Alpha1-antitrypsin deficiency but although emphysema is the dominant lung pathology bronchiectasis is also present in 27% of emphysema cases and may require a different treatment strategy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
6. Alpha-1 antitrypsin deficiency as a common treatable mechanism in chronic respiratory disorders and for conditions different from pulmonary emphysema? A commentary on the new European Respiratory Society statement
- Author
-
Gramegna, Andrea, Aliberti, Stefano, Confalonieri, Marco, Corsico, Angelo, Richeldi, Luca, Vancheri, Carlo, and Blasi, Francesco
- Published
- 2018
- Full Text
- View/download PDF
7. Genetic and Serum Screening for Alpha-1-Antitrypsin Deficiency in Adult Patients with Cystic Fibrosis: A Single-Center Experience.
- Author
-
Amati, Francesco, Gramegna, Andrea, Contarini, Martina, Stainer, Anna, Curcio, Cristina, Aliberti, Stefano, Corsico, Angelo Guido, and Blasi, Francesco
- Subjects
ALPHA 1-antitrypsin deficiency ,CYSTIC fibrosis ,GENETIC testing ,ADULTS ,DEMOGRAPHIC characteristics - Abstract
Cystic fibrosis (CF) and alpha-1 antitrypsin (AAT) deficiency are two of the commonest genetic diseases affecting the Caucasian population. Neutrophil-mediated inflammation due to protease–antiprotease imbalance leads to progressive pulmonary involvement in both diseases. The aim of this study was to investigate the prevalence of AAT deficiency in CF adults. A prospective study enrolling CF adults was conducted at the Adult CF Center based in Milan from January 2018 to March 2019. Patients were tested for AAT serum protein quantification and expanded genotyping characterization of SERPINA1 during clinical stability. Genotyping characterization of SERPIN1 was compared to a control population of 2848 Caucasian individuals with the same geographical origin and similar demographic characteristics. Among 173 patients included in the study, the prevalence of AAT deficiency was 0. Genotype analysis was piMM in 166 (94.9%) patients and piMS in 9 patients (5.1%), respectively. No differences in terms of genotype characterization were found between the CF population and the control population. These data show that AAT deficiency is not common among adults with CF. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
8. Validation of Murray sputum purulence scale in the Italian Registry of Bronchiectasis (IRIDE)
- Author
-
Nunzio Crimi, Carla Galeone, Stefano Aliberti, Angelo Corsico, Martina Contarini, Meridiana Dodaj, Valentina Conio, Nicola Scichilone, Vittoria Comellini, Andrea Gramegna, Emanuela De Juli, Giovanni Sotgiu, Francesco Blasi, Paola Faverio, Francesco Menzella, Francesco Amati, Salvatore Battaglia, Elisa Franceschi, Marialma Berlendis, Pierluigi Paggiaro, Cecilia Calabrese, Sebastian Ferri, Federico L. Dente, Stefano Nava, Rosa Di Matteo, Maurizio Dottorini, James D. Chalmers, Franceschi, Elisa, Aliberti, Stefano, Dente, Federico, Berlendis, Marialma, De Juli, Emanuela, Battaglia, Salvatore, Gramegna, Andrea, Amati, Francesco, Contarini, Martina, Calabrese, Cecilia, Conio, Valentina, Comellini, Vittoria, Crimi, Nunzio, Corsico, Angelo, Faverio, Paola, Ferri, Sebastian, Galeone, Carla, Menzella, Francesco, Nava, Stefano, Paggiaro, Pierluigi, Scichilone, Nicola, Dottorini, Maurizio, Di Matteo, Rosa, Dodaj, Meridiana, D Chalmers, Jame, Sotgiu, Giovanni, and Blasi, Francesco
- Subjects
medicine.medical_specialty ,Bronchiectasis ,Sputum colour ,Copd patients ,business.industry ,Sputum Production ,medicine.disease ,Disease severity ,Internal medicine ,Secondary analysis ,Cohort ,medicine ,Sputum ,medicine.symptom ,business - Abstract
Introduction: Murray sputum colour chart stratifies patients according to the presence of mucous (M), muco-purulent (MP) or purulent (P) sputum, and has not been validated in Bx yet. We aimed to validate this scale across a large Italian cohort of Bx patients. Methods: A secondary analysis of the IRIDE database was conducted including adults with Bx and daily sputum production enrolled across 13 Italian centres between 2014 and 2017. M vs. MP vs. P sputum producers were identified and clinical, functional and microbiological data were collected. Clinical outcomes during a two-year follow up period were evaluated in the Monza and Milan cohorts. A sensitivity analysis excluding COPD patients was conducted. Results: 448 patients were enrolled (65% female, median age 68 years): 45% belonged to Group M, 40% to Group MP and 15% to Group P. Significant differences (M vs. MP vs. P) were detected in terms of rate of chronic infection due to any bacteria (30% vs. 47% vs. 71%, p
- Published
- 2018
9. Quality standards for the management of bronchiectasis in Italy: A national audit
- Author
-
Maria Pia Foschino Barbaro, Stefano Aliberti, Valentina Conti, Francesco De Blasio, Mauro Carone, Antonio Foresi, Marina Saetta, Marialma Berlendis, Giuseppe Girbino, Pierachille Santus, Michele Vitacca, Salvatore Lo Cicero, Donato Lacedonia, Stefano Centanni, Nicola Ciancio, Vittoria Comellini, Daniela Bonardi, Fulvio Braido, G. F. Schiraldi, Francesca Becciu, Angelo Corsico, Nunzio Crimi, Giuseppe Francesco Sferrazza Papa, Adam T. Hill, Pietro Schino, Piero Ceriana, Alessandro Vatrella, Francesco Menzella, Alessandro Sanduzzi, Carmela Morrone, Pierfranco Usai, Mario Malerba, Caterina Conti, Marco Basile, Sergio Celestino Conte, Marco Mantero, Salvatore Battaglia, Francesco Blasi, Kim Lokar-Oliani, James D. Chalmers, Vincenzo Mastrosimone, Claudia Stochino, Aliberti, S., Hill, A., Mantero, M., Battaglia, S., Centanni, S., Cicero, S., Lacedonia, D., Saetta, M., Chalmers, J., Blasi, F., Morrone, C., Basile, M., Papa, G., Conti, C., Barbaro, M., Lokar-Oliani, K., Schino, P., Vitacca, M., Menzella, F., Sanduzzi, A., Usai, P., Carone, M., Bonardi, D., Crimi, N., Schiraldi, G., Corsico, A., Malerba, M., Becciu, F., Santus, P., Girbino, G., Foresi, A., Comellini, V., Stochino, C., Ceriana, P., Conti, V., Braido, F., Mastrosimone, V., Ciancio, N., Berlendis, M., De Blasio, F., Conte, S., Vatrella, A., Aliberti, Stefano, Hill, Adam T., Mantero, Marco, Battaglia, Salvatore, Centanni, Stefano, Cicero, Salvatore Lo, Lacedonia, Donato, Saetta, Marina, Chalmers, James D., Blasi, Francesco, Morrone, Carmela, Basile, Marco, Papa, Giuseppe Francesco Sferrazza, Conti, Caterina, Barbaro, Maria Pia Foschino, Lokar Oliani, Kim, Schino, Pietro, Vitacca, Michele, Menzella, Francesco, SANDUZZI ZAMPARELLI, Alessandro, Usai, Pierfranco, Carone, Mauro, Bonardi, Daniela Rita, Crimi, Nunzio, Schiraldi, Gianfranco, Corsico, Angelo, Malerba, Mario, Becciu, Francesca, Santus, Pierachille, Girbino, Giuseppe, Foresi, Antonio, Comellini, Vittoria, Stochino, Claudia, Ceriana, Piero, Conti, Valentina, Braido, Fulvio, Mastrosimone, Vincenzo, Ciancio, Nicola, Berlendis, Marialma, De Blasio, Francesco, Conte, Sergio Celestino, and Vatrella, Alessandro
- Subjects
Male ,Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,bronchiectasis ,media_common.quotation_subject ,Symptom Flare Up ,Medical audit ,Settore MED/10 - Malattie Dell'Apparato Respiratorio ,03 medical and health sciences ,0302 clinical medicine ,medicine ,Prevalence ,Humans ,Quality (business) ,Pseudomonas Infections ,030212 general & internal medicine ,Intensive care medicine ,National audit ,media_common ,Aged ,Medical Audit ,Bronchiectasis ,business.industry ,Medicine (all) ,Middle Aged ,medicine.disease ,Anti-Bacterial Agents ,Patient Care Management ,030228 respiratory system ,Italy ,Needs assessment ,Pseudomonas aeruginosa ,Female ,business ,Needs Assessment - Abstract
Although historically considered a neglected disease, bronchiectasis has become a disease of renewed interest over recent decades in light of an increase in prevalence and a substantial burden on healthcare systems. In 2010, the British Thoracic Society (BTS) published guidelines on the management of bronchiectasis in adults, along with specific quality standards. To date, these represent the only quality standards available in Europe. These have been tested over a number of years in the UK with progressive improvements in the standard of care. No national guidelines are available in Italy and no indications on which guideline should be followed have been given by the Italian Society of Respiratory Medicine (SIP). There are limited published data on the quality of bronchiectasis care in Europe outside of the UK. The BTS standards have not been tested in continental Europe or in Italy, where information on characteristics and management of bronchiectasis patients are lacking.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.